The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study

• DOI: 10.1007/s00432-014-1789-x
• Publication Date: 2014-08-02T05:29:20Z
• Authors: Paweł Krawczyk; Rodryg Ramlau; Joanna Chorostows...; Tomasz Powrózek; Marzena Anna Lewa...; Janusz Limon; Bartosz Wasąg; Juliusz Pankowski; Jerzy Kozielski; Ewa Kalinka-Warzocha; Aleksandra Szczęsna; Kamila Wojas-Kraw...; Michał Skroński; Rafał Dziadziuszko; Paulina Jaguś; Ewelina Antoszewska; Justyna Szumiło; Bożena Jarosz; Aldona Woźniak; Wojciech Jóźwicki; Wojciech Dyszkiewicz; Monika Pasieka-Lis; Dariusz M. Kowalski; Maciej Krzakowski; Jacek Jassem; Janusz Milanowski
• Keywords: Hematology

Testing for the epidermal growth factor receptor (EGFR) gene mutations requires considerable multidisciplinary experience of clinicians (for appropriate patient selection), pathologists selection cytological or histological material) and geneticists performing reporting reliable molecular tests). We present our on efficacy routine EGFR testing in various types tumor samples frequency a large series Polish non-small cell lung cancer (NSCLC) patients.Deletions exon 19 substitution L858R 21 were assessed using real-time PCR techniques 1,138 small biopsies specimens 1,312 surgical samples.Out 2,450 diagnostic (containing >10% cells), occurrence was 9%; more frequently women (13.9%) adenocarcinoma patients (10%), particularly with accompanying expression TTF1 (13.0%). The similar specimens, primary metastatic lesions, did not depend percentage cells quality isolated DNA. Cytological biopsy, compared to showed lower cells, no impact assay.Cytological biopsy low (10-20%) content from lesions are sufficient source mutation NSCLC patients. incidence examined population those reported other Caucasian populations.